• 1.

    Wanner C, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:32334.

  • 2.

    Heerspink HJ, et al.. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28:36875.

  • 3.

    Heerspink HJ, et al.. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016; 18:5907.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Fernández-Balsells MM, Sojo-Vega L, Ricart-Engel W. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:2098.

    • Search Google Scholar
    • Export Citation
  • 5.

    Kodera R, Shikata K. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor. J Diabetes Investig 2016; 7:2931.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Mosenzon O, et al.. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 2017; 40:6976.

  • 7.

    Cornel JH, et al.. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care 2016; 39:230410.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther Adv Endocrinol Metab 2013; 4:95105.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Kodera R, et al.. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54:96578.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377:839848.

    • Crossref
    • Search Google Scholar
    • Export Citation

Newer diabetic medications and the kidney

  • 1 Sonali Gupta, MD, is a resident, and
  • | 2 Joseph Mattana, MD, is Chairman, Department of Medicine, at St. Vincent’s Medical Center in Bridgeport, CT. Dr. Mattana is a member of the KN Editorial Advisory Board.
Restricted access
Save